Blissenbachs direct contact information and can reach the Blissful Wellness team during business hours via phone, text, or secure messaging
Under federal law, compounding can be appropriate when a patient requires a different dosage or formulation from what is commercially available
Patients lose fat in the cheeks, temples, and jawline faster than the skin can adapt, creating a gaunt or hollow appearance even when their body weight and overall health have improved significantly
Top-line outcomes at the 48-week primary endpoint, by dose: Notable Phase 2 finding particularly relevant to the 10mg vial: the 1mg/week cohort still produced 8.7% mean weight loss over 48 weeks, clinically meaningful activity even at sub-therapeutic doses relative to the 12mg maximum
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%
Frequently Asked Questions Yes
